NASDAQ:ITOS - Nasdaq - US46565G1040 - Common Stock - Currency: USD
Let's have a look at the gap up and gap down stocks in today's session.
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended.
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring...
Upon closing, it will be the 10th international consumer business Citi has sold since 2021. The bank will maintain its institutional business in Poland, as it has elsewhere, following the sale.
Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid to "maximize" shareholder value.
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Trump Incentivizes Pharmaceuticals to Build Domestic Manufacturing Capacity […]
– GALAXIES Lung-201 erfüllte nicht die festgelegten Kriterien für klinisch bedeutsame Verbesserungen beim progressionsfreien Überleben – Ausgehend von der...
– L’étude GALAXIES Lung-201 n’a pas satisfait aux critères établis pour une amélioration cliniquement significative de la survie sans progression – Sur la...
The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.
GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks for a new generation of immunotherapy medicines.
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data,...
The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Topline-Zwischenergebnisse von GALAXIES Lung-201 mit >240 Patienten im 2. Quartal 2025 erwartet - Zwischenergebnisse von GALAXIES H&N-202 und...
- Données de haut niveau provisoires issues de l’essai GALAXIES Lung-201, et plus de 240 patients attendus au deuxième trimestre 2025 - Données...
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006...
WATERTOWN, Mass. und GOSSELIES, Belgien, March 26, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), ein biopharmazeutisches Unternehmen...
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 26 mars 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique...
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...
- Topline-Zwischendatensatz von GALAXIES Lung-201 mit >240 Patienten für das 2. Quartal 2025 erwartet - Zwischendatensätze von GALAXIES H&N-202 und...
- Données provisoires de haut niveau issues de l’étude GALAXIES Lung-201 portant sur plus de 240 patients prévues pour le 2ᵉ trimestre 2025- Données...
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC...
- Plusieurs extractions de données cliniques issues du programme TIGIT attendues en 2025, portant sur plus de 400 patients issus de deux essais de Phase II...
- Im Laufe des Jahres 2025 werden mehrere im Rahmen des TIGIT-Programms durchgeführte Analysen klinischer Daten erwartet, darunter jene zu > 400...